(Q41615112)

5 October 2017

1 reference

title

Losartan, an orally active angiotensin (AT1) receptor antagonist: a review of its efficacy and safety in essential hypertension (English)

1 reference

5 October 2017

1 reference

McIntyre M

1

1 reference

5 October 2017

Caffe SE

series ordinal

2

1 reference

5 October 2017

Michalak RA

series ordinal

3

1 reference

5 October 2017

Reid JL

series ordinal

4

1 reference

5 October 2017

publication date

1 January 1997

1 reference

Pharmacology & Therapeutics

5 October 2017

published in

1 reference

5 October 2017

volume

74

1 reference

5 October 2017

issue

2

1 reference

5 October 2017

page(s)

181-194

1 reference

Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives

5 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2897%2982002-5

7 January 2021

Clinical pharmacology of the angiotensin II receptor antagonist losartan potassium in healthy subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2897%2982002-5

7 January 2021

Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2897%2982002-5

7 January 2021

Human plasma protein binding of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK 954) and its pharmacologically active metabolite EXP3174

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2897%2982002-5

7 January 2021

Dose-response relationships following oral administration of DuP 753 to normal humans

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2897%2982002-5

7 January 2021

Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2897%2982002-5

7 January 2021

Comparison of angiotensin-converting enzyme inhibition with angiotensin II receptor antagonism in the human forearm

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2897%2982002-5

7 January 2021

Blood pressure, stroke, and coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2897%2982002-5

7 January 2021

Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2897%2982002-5

7 January 2021

Effect of multiple doses of losartan on the pharmacokinetics of single doses of digoxin in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2897%2982002-5

7 January 2021

Haemodynamic and Renal Responses to Oral Losartan Potassium During Salt Depletion or Salt Repletion in Normal Human Volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2897%2982002-5

7 January 2021

Simultaneous determination of a novel angiotensin II receptor blocking agent, losartan, and its metabolite in human plasma and urine by high-performance liquid chromatography

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2897%2982002-5

7 January 2021

Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2897%2982002-5

7 January 2021

Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2897%2982002-5

7 January 2021

Effects of cimetidine on pharmacokinetics and pharmacodynamics of losartan, an AT1-selective non-peptide angiotensin II receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2897%2982002-5

7 January 2021

Differential effects of oral losartan and enalapril on local venous and systemic pressor responses to angiotensin I and II in healthy men

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2897%2982002-5

7 January 2021

Phenobarbital minimally alters plasma concentrations of losartan and its active metabolite E-3174

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2897%2982002-5

7 January 2021

Group sequential extensions of a standard bioequivalence testing procedure

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2897%2982002-5

7 January 2021

A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2897%2982002-5

7 January 2021

1993 guidelines for the management of mild hypertension: memorandum from a World Health Organization/International Society of Hypertension meeting. Guidelines Sub-Committee

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2897%2982002-5

7 January 2021

Comparative antihypertensive effects of losartan 50 mg and losartan 50 mg titrated to 100 mg in patients with essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2897%2982002-5

7 January 2021

Losartan does not affect the pharmacokinetics and pharmacodynamics of warfarin

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2897%2982002-5

7 January 2021

Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2897%2982002-5

7 January 2021

Maintenance of blood pressure by the renin–angiotensin system in normal man

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2897%2982002-5

7 January 2021

Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2897%2982002-5

7 January 2021

Antihypertensive efficacy and tolerability of once daily losartan potassium compared with captopril in patients with mild to moderate essential hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2897%2982002-5

7 January 2021

Absence of a pharmacokinetic interaction between losartan and hydrochlorothiazide.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2897%2982002-5

7 January 2021

Comparison of the oral angiotensin II receptor antagonist UP 269-6 or enalapril 20 mg on blood pressure and neurohormonal effects in salt-deplete man

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2897%2982002-5

7 January 2021

Dose-ranging study of the angiotensin II receptor antagonist irbesartan (SR 47436/BMS-186295) on blood pressure and neurohormonal effects in salt-deplete men

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2897%2982002-5

7 January 2021

Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2897%2982002-5

7 January 2021

Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2897%2982002-5

7 January 2021

Double-blind comparison of losartan, lisinopril and hydrochlorothiazide in hypertensive patients with a previous angiotensin converting enzyme inhibitor-associated cough

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2897%2982002-5

7 January 2021

Comparative effects of combination drug therapy regimens commencing with either losartan potassium, an angiotensin II receptor antagonist, or enalapril maleate for the treatment of severe hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2897%2982002-5

7 January 2021

Controlled trial of losartan given concomitantly with different doses of hydrochlorothiazide in hypertensive patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2897%2982002-5

7 January 2021

Treatment of mild to moderate hypertension with or without the converting enzyme inhibitor enalapril. Results of a six-month double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2897%2982002-5

7 January 2021

Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2897%2982002-5

7 January 2021

Genetics of primary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2897%2982002-5

7 January 2021

Effects of Losartan on a Background of Hydrochlorothiazide in Patients With Hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2897%2982002-5

7 January 2021

The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2897%2982002-5

7 January 2021

Pharmacodynamic activity of intravenous E-3174, an angiotensin II antagonist, in patients with essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2897%2982002-5

7 January 2021

Angiotensin II-forming pathways in normal and failing human hearts

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2897%2982002-5

7 January 2021

Blood pressure effects of the angiotensin II receptor blocker, losartan

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2897%2982002-5

7 January 2021

10.1016/S0163-7258(97)82002-5

Identifiers

DOI

1 reference

5 October 2017

1 reference